Always investing in new research for its historic ingredient, the acacia fibre, Nexira releases a new trial on humans showing the benefit of inavea pure acacia on transit modulation and its extreme tolerability on sensitive people with IBS.
According to the results of the Rome Foundational study, it was found that across 33 countries on six continents, more than 40% of persons worldwide suffer with a functional gastrointestinal disorder, such as IBS, and this dramatically affects their quality of life and healthcare use. Across Europe, consumer spending on OTC and supplements is considerable. Diets and supplements have crucial roles in managing these disorders, and brands can play a part.
With more than 40 years of research in gut and microbiome, Nexira continues to complete its expertise and has released new study results on its prebiotic fibre.
As part of the IBSQUtrition project (2017-2022), Wageningen University & Research and its partners have conducted important research on people with irritable bowel syndrome (IBS) using nutrition. “Nexira has joined this consortium to learn more about the effect of its acacia fibre on transit”, explained Damien Guillemet, Nexira Scientific Director.
Preclinical studies have demonstrated the benefit of inavea pure acacia on transit and digestive comfort.
An interventional double-blinded clinical study vs placebo has been realised (publication in progress). inavea pure acacia has been evaluated on 120 persons from the predominantly constipated category of IBS people. They have taken 10g of inavea pure acacia during 4 weeks, vs placebo.
One of the most important threats for fibre intake is the associated digestive discomfort. That said, these results supporting the digestive comfort are certainly a major asset for inavea pure acacia
inavea pure acacia has demonstrated its potency by significantly improving constipation for IBS people. “It was the first time that acacia fibre has demonstrated its benefit on transit modulation in adults”, said Guillemet.
“Talking about constipation or transit seems to be old fashioned in front of microbiome, -biotics and so on. However, with more than 40% of people worldwide suffering from a functional gastrointestinal disorder, this solution to improve transit still has a huge potential for supplement manufacturers”, added Julie Impérato, Nexira Marketing manager. In addition, according to EFSA guidelines, this improvement of transit is also valuable for occasional constipation in the general population.
A secondary end point of the study was about digestive comfort. Nexira has previously demonstrated that acacia fibre is highly tolerable, especially compared to FOS. The interesting point of this latest study is that inavea pure acacia was compatible with the IBS population, known to be highly sensitive. “inavea supplementation did not trigger higher severity scores or symptoms and even tends to decrease them”, completed Guillemet.
“One of the most important threats for fibre intake is the associated digestive discomfort. That said, these results supporting the digestive comfort are certainly a major asset for inavea pure acacia”, added Impérato.
These new results confirm that inavea pure acacia supports transit modulation by improving constipation, with a high digestive comfort. Thanks to its properties, inavea pure acacia can be used in a large array of applications, from supplements in powder to functional food and beverage such as trendy carbonates, functional alt-dairy or convenient bars, which open the field of innovation and new concepts.
